伊利-普罗-普罗减弱了同情活动和高血压
Jun-Liu Chen1, Rui Ge1, Xiu-Zhen Li2
1Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu, 211166, China.
Journal of physiology and biochemistry
|July 15, 2024
概括
胰岛素-氨酸-氨酸 (IPP) 通过抑制血管酶转化酶 (ACE) 和氧化应激,降低高血压和交感神经活动. 这三显示出通过中央和外围机制治疗高血压的潜力.
科学领域:
- 心血管生理学心血管生理学
- 神经研究 神经研究
- 高血压治疗药物 高血压治疗药物
背景情况:
- 单氨酸-氨酸-氨酸 (IPP) 是一种已知可以抑制血管素转化酶 (ACE) 的食物衍生的三.
- 交感性过度活动和氧化应激是导致高血压的关键因素.
- 了解IPP的中心和外围作用对于其治疗潜力至关重要.
研究的目的:
- 研究IPP在调节同情活动,氧化应激和高血压中的作用.
- 确定IPP在中枢神经系统和外周循环中产生作用的机制.
主要方法:
- 在Sprague-Dawley大鼠中诱导血管高血压,使用双一 (2K1C) 模型.
- 直接的IPP微注射到下丘脑侧心脏核 (PVN) 和静脉注射.
- 测量交感神经活动,血压,评估ACE活动和氧化应激标志物.
主要成果:
- 在2K1C大鼠中,IPP的中央 (PVN) 和外周 (静脉) 给药显著减弱了交感活动和血压.
- IPP抑制了ACE活性,并减少了PVN和动脉中的超氧化物产生.
- 长期的腹腔内IPP治疗改善了高血压,血管改造和氧化应激.
结论:
- 通过抑制ACE和氧化应激,IPP有效地减轻高血压和同情活动.
- 外围IPP的交感抑制作用主要通过PVN内的ACE抑制来介导.
- IPP显示出对高血压的治疗潜力,影响中央和外围机制,减少血管损伤.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
600
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
600
Antihypertensive Drugs: Action of β1 Blockers
411
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
411
Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502
Antihypertensive Drugs: Types of β-Blockers
633
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
633
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
684
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
684


